NBM-HD-1: A novel histone deacetylase inhibitor with anticancer activity

Evidence-based Complementary and Alternative Medicine

Volumn 2012, Issue , 2012, Pages

  Huang, Wei Jan ^a   Liang, Yu Chih ^a   Chuang, Shuang En ^b   Chi, Li Ling ^c   Lee, Chi Yun ^c   Lin, Chia Wei ^c   Chen, Ai Ling ^c   Huang, Jing Shi ^c   Chiu, Chun Jung ^c   Lee, Cheng Feng ^c   Huang, Chung Yang ^c   Chen, Chia Nan ^c  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^c ACADEMIA SINICA   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLIN B1; CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR 1; GELSOLIN; HISTONE DEACETYLASE INHIBITOR; HISTONE H4; MITOGEN ACTIVATED PROTEIN KINASE; NMB HD 1; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; TUBULIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL; CANCER INHIBITION; CONTROLLED STUDY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME ACTIVITY; FEMALE; GENE EXPRESSION; GLIOMA CELL; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; RAT; TUMOR SUPPRESSOR GENE; TUMOR XENOGRAFT; UPREGULATION;

EID: 84855182267     PISSN: 1741427X     EISSN: 17414288     Source Type: Journal    
DOI: 10.1155/2012/781417     Document Type: Article

References (44)

1. DeLange R. J., Smith E. L., Histones: structure and function Annual Review of Biochemistry 1971 40 279 314
2. Ris H., Kubai D. F., Chromosome structure Annual Review of Genetics 1970 4 263 294
3. Back F., The variable condition of euchromatin and heterochromatin International Review of Cytology 1976 45 25 64
4. Berlowitz L., Pallotta D., Acetylation of nuclear protein in the heterochromatin and euchromatin of mealy bugs Experimental Cell Research 1972 71 1 45 48
5. Papait R., Monti E., Bonapace I. M., Novel approaches on epigenetics Current Opinion in Drug Discovery and Development 2009 12 2 264 275
6. Turner B. M., Histone acetylation and an epigenetic code BioEssays 2000 22 9 836 845
7. Hager G. L., McNally J. G., Misteli T., Transcription dynamics Molecular Cell 2009 35 6 741 753
8. Clapier C. R., Cairns B. R., The biology of chromatin remodeling complexes Annual Review of Biochemistry 2009 78 273 304
9. Miremadi A., Oestergaard M. Z., Pharoah P. D. P., Caldas C., Cancer genetics of epigenetic genes Human Molecular Genetics 2007 16 1 R28 R49
10. Mottet D., Castronovo V., Histone deacetylases: target enzymes for cancer therapy Clinical and Experimental Metastasis 2008 25 2 183 189
11. Selvi B. R., Kundu T. K., Reversible acetylation of chromatin: implication in regulation of gene expression, disease and therapeutics Biotechnology Journal 2009 4 3 375 390
12. Atadja P. W., HDAC inhibitors and cancer therapy Progress in Drug Research 2011 67 175 195
13. Esteller M., Epigenetics in cancer The New England Journal of Medicine 2008 358 11 1148 1159
14. Chen W. Y., Bailey E. C., McCune S. L., Dong J. Y., Townes T. M., Reactivation of silenced, virally transduced genes by inhibitors of histone deacetylase Proceedings of the National Academy of Sciences of the United States of America 1997 94 11 5798 5803 (Pubitemid 27241851)
15. Sutherland J. E., Peng W., Zhang Q. W., Costa M., The histone deacetylase inhibitor trichostatin A reduces nickel-induced gene silencing in yeast and mammalian cells Mutation Research 2001 479 1-2 225 233 (Pubitemid 32695503)
16. Cherrier T., Suzanne S., Redel L., Calao M., Marban C., Samah B., Mukerjee R., Schwartz C., Gras G., Sawaya B. E., Zeichner S. L., Aunis D., Van Lint C., Rohr O., p21 (WAF1) gene promoter is epigenetically silenced by CTIP2 and SUV39H1 Oncogene 2009 28 38 3380 3389
17. Zhang Y., Carr T., Dimtchev A., Zaer N., Dritschilo A., Jung M., Attenuated DNA damage repair by trichostatin a through BRCA1 suppression Radiation Research 2007 168 1 115 124 (Pubitemid 351292932)
18. Cantor J. P., Iliopoulos D., Rao A. S., Druck T., Semba S., Han S. Y., McCorkell K. A., Lakshman T. V., Collins J. E., Wachsberger P., Friedberg J. S., Huebner K., Epigenetic modulation of endogenous tumor suppressor expression in lung cancer xenografts suppresses tumorigenicity International Journal of Cancer 2007 120 1 24 31 (Pubitemid 44901913)
19. Prince H. M., Bishton M. J., Johnstone R. W., Panobinostat (LBH589): a potent pan-deacetylase inhibitor with promising activity against hematologic and solid tumors Future Oncology 2009 5 5 601 612
20. Stimson L., Wood V., Khan O., Fotheringham S., La Thangue N. B., HDAC inhibitor-based therapies and haematological malignancy Annals of Oncology 2009 20 8 1293 1302
21. Richon V. M., Garcia-Vargas J., Hardwick J. S., Development of vorinostat: current applications and future perspectives for cancer therapy Cancer Letters 2009 280 2 201 210
22. Dickinson M., Johnstone R. W., Prince H. M., Histone deacetylase inhibitors: potential targets responsible for their anti-cancer effect Investigational New Drugs 2010 28 supplement 1 S3 S20
23. Bracker T. U., Sommer A., Fichtner I., Faus H., Haendler B., Hess-Stumpp H., Efficacy of MS-275, a selective inhibitor of class I histone deacetylases, in human colon cancer models International Journal of Oncology 2009 35 4 909 920
24. Sasaki Y., Negishi H., Idogawa M., Suzuki H., Mita H., Toyota M., Shinomura Y., Imai K., Tokino T., Histone deacetylase inhibitor FK228 enhances adenovirus-mediated p53 family gene therapy in cancer models Molecular Cancer Therapeutics 2008 7 4 779 787 (Pubitemid 351551031)
25. Xu W. S., Parmigiani R. B., Marks P. A., Histone deacetylase inhibitors: molecular mechanisms of action Oncogene 2007 26 37 5541 5552 (Pubitemid 47255934)
26. Arts J., Angibaud P., Marin A., Floren W., Janssens B., King P., Van Dun J., Janssen L., Geerts T., Tuman R. W., Johnson D. L., Andries L., Jung M., Janicot M., Van Emelen K., R306465 is a novel potent inhibitor of class I histone deacetylases with broad-spectrum antitumoral activity against solid and haematological malignancies The British Journal of Cancer 2007 97 10 1344 1353 (Pubitemid 350114783)
27. Ma X., Ezzeldin H. H., Diasio R. B., Histone deacetylase inhibitors: current status and overview of recent clinical trials Drugs 2009 69 14 1911 1934
28. Konstantinopoulos P. A., Vandoros G. P., Papavassiliou A. G., FK228 (depsipeptide): a HDAC inhibitor with pleiotropic antitumor activities Cancer Chemotherapy and Pharmacology 2006 58 5 711 715 (Pubitemid 44167398)
29. Shankar S., Srivastava R. K., Histone deacetylase inhibitors: mechanisms and clinical significance in cancer: HDAC inhibitor-induced apoptosis Advances in Experimental Medicine and Biology 2008 615 261 298
30. Huang W. J., Huang C. H., Wu C. L., Lin J. K., Chen Y. W., Lin C. L., Chuang S. E., Huang C. Y., Chen C. N., Propolin G, a prenylflavanone, isolated from Taiwanese propolis, induces caspase-dependent apoptosis in brain cancer cells Journal of Agricultural and Food Chemistry 2007 55 18 7366 7376
31. Caldon C. E., Daly R. J., Sutherland R. L., Musgrove E. A., Cell cycle control in breast cancer cells Journal of Cellular Biochemistry 2006 97 2 261 274 (Pubitemid 43167144)
32. Gartel A. L., p21 (WAF1/CIP1) and cancer: a shifting paradigm? BioFactors 2009 35 2 161 164
33. Egloff A. M., Vella L. A., Finn O. J., Cyclin B1 and other cyclins as tumor antigens in immunosurveillance and immunotherapy of cancer Cancer Research 2006 66 1 6 9 (Pubitemid 43165999)
34. Kim J. K., Diehl J. A., Nuclear cyclin D1: an oncogenic driver in human cancer Journal of Cellular Physiology 2009 220 2 292 296
35. Chen H. Z., Tsai S. Y., Leone G., Emerging roles of E2Fs in cancer: an exit from cell cycle control Nature Reviews Cancer 2009 9 11 785 797
36. Satyanarayana A., Kaldis P., Mammalian cell-cycle regulation: several Cdks, numerous cyclins and diverse compensatory mechanisms Oncogene 2009 28 33 2925 2939
37. Esteller M., Profiling aberrant DNA methylation in hematologic neoplasms: a view from the tip of the iceberg Clinical Immunology 2003 109 1 80 88 (Pubitemid 37324745)
38. Vigushin D. M., Coombes R. C., Histone deacetylase inhibitors in cancer treatment Anti-Cancer Drugs 2002 13 1 1 13 (Pubitemid 34169522)
39. Arts J., King P., Marin A., Floren W., Belin A., Janssen L., Pilatte I., Roux B., Decrane L., Gilissen R., Hickson I., Vreys V., Cox E., Bol K., Talloen W., Goris I., Andries L., Du Jardin M., Janicot M., Page M., Van Emelen K., Angibaud P., JNJ-26481585, a novel second-generation oral histone deacetylase inhibitor, shows broad-spectrum preclinical antitumoral activity Clinical Cancer Research 2009 15 22 6841 6851
40. Kelly W. K., Marks P. A., Drug insight: histone deacetylase inhibitorsdevelopment of the new targeted anticancer agent suberoylanilide hydroxamic acid Nature Clinical Practice Oncology 2005 2 3 150 157 (Pubitemid 40823166)
41. Kim D., Frank C. L., Dobbin M. M., Tsunemoto R. K., Tu W., Peng P. L., Guan J. S., Lee B. H., Moy L. Y., Giusti P., Broodie N., Mazitschek R., Delalle I., Haggarty S. J., Neve R. L., Lu Y., Tsai L. H., Deregulation of HDAC1 by p25/Cdk5 in neurotoxicity Neuron 2008 60 5 803 817
42. Huang W. J., Lin C. W., Lee C. Y., Chi L. L., Chao Y. C., Wang H. N., Chiou B. L., Chen T. J., Huang C. Y., Chen C. N., NBM-HD-3, a novel histone deacetylase inhibitor with anticancer activity through modulation of PTEN and AKT in brain cancer cells Journal of Ethnopharmacology 2011 136 1 156 167
43. Jeong J. M., Choi C. H., Kang S. K., Lee I. H., Lee J. Y., Jung H., Antioxidant and chemosensitizing effects of flavonoids with hydroxy and/or methoxy groups and structure-activity relationship Journal of Pharmacy Pharmaceutical Sciences 2007 10 4 537 546
44. Al-Janadi A., Chandana S. R., Conley B. A., Histone deacetylation: an attractive target for cancer therapy? Drugs in R D 2008 9 6 369 383